Vera Therapeutics Q3 2023 Earnings Report $49.38 -0.17 (-0.34%) (As of 12/3/2024 ET) Vera Therapeutics EPS ResultsActual EPS-$0.45Consensus EPS -$0.50Beat/MissBeat by +$0.05One Year Ago EPSN/AVera Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AVera Therapeutics Announcement DetailsQuarterQ3 2023Date11/9/2023TimeN/AConference Call ResourcesPress ReleaseVERA Earnings HistoryPowered by Even Trump can’t stop what’s coming. (Ad)No matter who sits in the White House over the next four years, a series of events has been triggered that could devastate millions of Americans. These events have caused five major cracks in our economy... That's why I have moved 7-figures of my own money out of the stock market.Watch my emergency briefing here >>> Vera Therapeutics Earnings HeadlinesJPMorgan updates its U.S. Analyst Focus List – Adds TPR, ALRM, REGNovember 25, 2024 | msn.comVera Therapeutics (NASDAQ:VERA) Coverage Initiated by Analysts at Wells Fargo & CompanyNovember 24, 2024 | americanbankingnews.comElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.December 4, 2024 | The Freeport Society (Ad)Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 22, 2024 | globenewswire.comWells Fargo Initiates Coverage of Vera Therapeutics (VERA) with Overweight RecommendationNovember 22, 2024 | msn.comVera Therapeutics (VERA) Gets a Buy from J.P. MorganNovember 21, 2024 | markets.businessinsider.comSee More Vera Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vera Therapeutics and other key companies, straight to your email. Email Address About Vera TherapeuticsVera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.View Vera Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report Upcoming Earnings Toronto-Dominion Bank (12/5/2024)Canadian Imperial Bank of Commerce (12/5/2024)Bank of Montreal (12/5/2024)Oracle (12/9/2024)Adobe (12/11/2024)Broadcom (12/12/2024)Costco Wholesale (12/12/2024)Accenture (12/17/2024)Micron Technology (12/18/2024)Paychex (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
